Navigation Links
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Date:8/19/2007

osive growth of clinical research in India. Mr. Maki's presentation is scheduled for 4:25 p.m.

About Cancer Cachexia and VT-122

Cancer cachexia results in severe wasting of muscle and connective tissue and is one of the most common debilitating and distressing conditions of advanced cancer. Severe cachexia is associated with extreme weakness, intolerance to chemotherapy and substantially reduced life expectancy. There is currently no FDA-approved therapy for cancer cachexia.

VT-122 targets inflammatory and other key pathways thought to be responsible for the onset and observed clinical symptoms of cancer cachexia. The use of VT-122 is currently being evaluated under a U.S. IND in a Phase 2 study being conducted concurrently at multiple sites in the U.S. and India. Results from the ongoing trial are expected by end of 2007.

About Vicus Therapeutics

Vicus Therapeutics is a privately-held, biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of cancer supportive care indications with an initial focus on cachexia. Vicus' strategy involves combining individual generic drugs that have previously received regulatory approval for other indications and thus have established post-marketing safety records. Vicus leverages its proprietary science to design and patent novel drug combinations that work together to reverse the body's maladaptive responses to cancer and its treatment. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of oral mucositis and cancer fatigue. Vicus' development programs are powered by its network of leading clinical investigators and partners in the US, India and Japan. This international network drives the high quality, rapid and cost effective clinical devel
'/>"/>

SOURCE Vicus Therapeutics

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... The International Myeloma Foundation (IMF) – improving ... toward prevention and a cure – today commended Representative ... resolution (H. Res. 174) that supports the designation of ... Awareness Month." Currently there are more than ... 110,000 new cases are diagnosed yearly, according to the ...
(Date:3/27/2015)... March 27, 2015  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the reporting of data from a ... for Injection with the Delcath Hepatic Delivery System ... at the Society of Surgical Oncology (SSO) Annual ...
(Date:3/26/2015)... PASADENA, Calif. , March 26, 2015 ... San Gabriel Valley to perform transcatheter aortic valve replacement ... TAVR procedure is a revolutionary new way to replace ... use of a heart lung machine. The ... heart team led by Azhil ( Alex) Durairaj , ...
Breaking Medicine Technology:The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
... Pharmaceuticals, Inc. today announced that Thomas Schreck, President & Chief ... will be presenting at the Lazard Capital Markets 6th Annual ... St. Regis Hotel, New York. , AcelRx Pharmaceuticals, presentation ... Time. , Mr. Schreck and Dr. Palmer will be ...
... Walt Maclay, President of Voler Systems ( ... on "Data Acquisition for Medical Devices" at BIOMEDevice,s ... http://www.devicelink.com/expo/biomed09/index.html ) is the premier event ... The show offers a compelling mix of new ...
Cached Medicine Technology:AcelRx to Present at the Lazard 6th Annual Healthcare Conference 2Voler Systems President Speaks at BIOMEDevice San Jose 2Voler Systems President Speaks at BIOMEDevice San Jose 3
(Date:3/27/2015)... 2015 According to a recently published ... plate and screw market in Europe is in decline ... and screw segment. Price decreases are being seen across ... 50% of the total European trauma device market, continued ... market value, year after year. , “Such price ...
(Date:3/27/2015)... Endure Yoga is launching WOD (Workout ... This new program matches yoga poses with functional fitness ... down. This program utilizes yoga to improve recovery, prevent ... , Karen Lefurgy, competitive athlete at CrossFit ... I started Crossfit® training, but quickly, due to time ...
(Date:3/27/2015)... FL and London, UK (PRWEB) March 27, 2015 ... announced today that it has appointed Sean Fitzgerald, a ... role of Chief Operating Officer and Interim Chief Financial ... President of leading education technology innovator, EverFi, backed by ... Schmidt, and Twitter founder Evan Williams. Prior to EverFi, ...
(Date:3/27/2015)... 2015 California’s ongoing worst ever drought, ... and the United States Northeast, are both manifestations of ... atmosphere is creating changes in the atmosphere’s “energy balance,” ... former NASA researcher, speaking on the Sharon Kleyne Hour™ ... only a warmer and dryer global climate but also ...
(Date:3/27/2015)... Trail mix is the perfect, healthy snack ... hikes and during the game! It’s portable, lightweight and provides ... to introduce a new line of specialty trail mixes that ... flavorful selections packed with nutritious, 100% all natural ingredients. , ... that add protein and fiber to your diet and boost ...
Breaking Medicine News(10 mins):Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:Endure Yoga Introduces WOD Recovery Yoga 2Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2
... Healthcare Innovation, Creating Local Jobs, LAWRENCE, Mass., ... local medical device manufacturer,NxStage Medical, Inc., at the ... a growing public company whose novel portable technology,makes ... have hemodialysis,treatment at home or where they travel, ...
... proteins, including,Hax1, work and how they control ... 29 Investigators at St.,Jude Children,s Research Hospital ... cells from undergoing apoptosis, also known as programmed,cell ... important to,researchers seeking ways to control this process., ...
... Provider to Offer Practice Management and Clinical, Software ... Health Care Providers, GREAT RIVER, N.Y., Feb. ... enterprise-wide software and services for health and,human services ... suite and operations from Nightingale VantageMed,Corporation, a subsidiary ...
... to Separate Medical ... Services Businesses, BATESVILLE, Ind., Feb. 29 Hillenbrand,Industries, Inc. ... has,commenced a cash tender offer to purchase any and all ... 431573AD6), of which $250,million in aggregate principal amount was outstanding ...
... face sparks a response in the adult brain , , FRIDAY, ... to go ga-ga when they see a baby? , ... face lit up a specific region of the adult brain ... when adults looked at another adult face, suggesting there,s a ...
... a book in the biological sciences proved as prescient as ... Tumours . Out of print for decades and previously almost ... a new and authoritative translation, co-published by Cold Spring Harbor ... the Origin of Malignant Tumours had a huge impact ...
Cached Medicine News:Health News:Tsongas Visits Lawrence-based Medical Device Maker NxStage Medical, Inc. 2Health News:St. Jude Researchers Find Key Step in Programmed Cell Death 2Health News:St. Jude Researchers Find Key Step in Programmed Cell Death 3Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 2Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 3Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 4Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 5Health News:Babies Really Can Light Up Your Life 2Health News:Babies Really Can Light Up Your Life 3
... the slight change in the difficulty score ... derived from the best corrected visual acuity ... study. The original charts difficulty scores were ... In addition to the revised arrangement of ...
... The Stereo Tower is used to ... and adults without the use of ... tests can be used for study, testing ... form and depth perception. The instruction card ...
... The Lang Stereotest was created to simplify stereopsis ... principles: random dots and cylindrical gratings. Lang Stereotest ... car 400 and elephant 600 seconds of arc ... II test, the random dots are smaller and ...
... three test plates(6mm, 3mm, and 1.5mm thick), which ... 600 - 15 seconds. No special glasses are ... if stereopsis is present. Test plates can be ... learning the correct answer. Large stereo acuity range. ...
Medicine Products: